Kornimate/medical-research-clean huggingface dataset:
development of a technique to predict antidepressant responsiveness in depressive patients

Conditions: Depression; Continuous Antidepressant Abuse; Adverse Reaction to Drug

Summary: first, the investigators examined the functional relevance of serotonin transporter polymorphisms by quantifying the activity of serotonin transporter in blood platelets of genotyped healthy volunteers and patients with major depression. second, the investigators studied response to ssris in relation to 5-httlpr genotype and also to the functional expression of 5-htt in platelets.

the purpose of this study is 1. to determine whether serotonin transporter genotypic or functional differences between depressive patients and normal controls were existed. 2. to determine the relationship between serotonin transporter polymorphisms and serotonin transporter functional expression. 3. to determine whether genomic or functional differences between drug responders and nonresponders predict the response of antidepressant

Eligibility criteria:
inclusion criteria: * eligible patients were enrolled in the clinical trials program of hte samsung medical center geropsychiatry and affective disorder clinics(seoul, korea). they received a semistructured diagnostic interview, the samsung psychiatric evaluation schedule. the affective disorder section of the samsung psychiatric evaluation schedule uses the korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, fourth edition. * interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians exclusion criteria: * received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks * potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant axis i psychiatric disorder.

Keywords: pharmacogenomics prediction of antidepressant response depressed patients
clinical outcome after treatment of patellar fractures with locking plates

Conditions: Fracture of Patella

Summary: depending on the fracture pattern of patellar fractures tension band wiring, interfragmentary screw fixation or combinations are common treatments. but there are several problems associated with these techniques as fracture dislocation or loosening and perforation of the wire. furthermore an anatomic reduction with stable fixation in comminuted fractures is almost impossible to achieve. a new option in the treatment of patellar fractures is the locking plate osteosynthesis, which provides a more stable fixation and higher mechanical strength in biomechanical tests compared to classic tension band wiring. due to various screw positioning a stable fixation in comminuted fractures can be achieved and an early functional treatment with full weight bearing reduces the loss of knee-motion. furthermore a removal of the osteosynthesis seems not to be essential anymore and the blood supply is not to be compromised. because of the absent of clinical evidence investigators want to evaluate the clinical outcome after locking plate osteosyntheses in patellar fractures and compare patient satisfaction, functional motion, complications and number of revisions with common treatments.


Eligibility criteria:
inclusion criteria: * patients with indication for operative treatment of a patellar fracture * sufficient compliance * signed patient information exclusion criteria: * preoperative disease or trauma of the patellar * preoperative loss of motion of the knee * former operations of the patellar * alcohol or drug consumption

Keywords: patellar fracture fracture of patella patella locking plate osteosynthesis osteosynthesis star-plate arrow-plate
salvage lymph node dissection in prostate cancer patients with recurrence after radical prostatectomy

Conditions: Prostate Cancer Recurrent

Summary: despite continuous technical improvements in urologic surgery, up to 40% of prostate cancer patients will develop biochemical recurrence after radical prostatectomy (rp), potentially because of micro metastasis at the time of the primary surgery. with improved radiological modalities and nuclear medicine tracers like 68ga-psma pet/ct, which allow the localization of the site of recurrence, there is increasing interest in metastasis directed therapies, such as salvage lymph node dissection. the pelvic extended salvage lymph node dissection (slnd) is a promising option for treating prostate cancer patients with local recurrence after radical prostatectomy with curative intent. several retrospective series has been published to determine the local value of slnd. despite the first data seem to be feasible and promising, to date no prospective evaluation has been made. thus slnd is still experimental according to the guidelines and is considered as an off label therapy. this prospective single center phase i/ii study was conducted to investigate the safety and early efficacy of salvage lymph node dissection in prostate cancer patients with local pelvic recurrence after radical prostatectomy (rp) with curative intention.


Eligibility criteria:
inclusion criteria: * prostate cancer patients with lymph node metastasis in pelvic imaging * status post radical prostatectomy with curative intent * ability for informed consent * no sign for bone or visceral metastasis * male \> 18 years * ecog performance status 0 or 1 exclusion criteria: * male \< 18 years * no ability for informed consent * sign for bone or visceral metastasis * deep venous thrombosis or pulmonary embolism within the last 6 months before study screening * ecog performance status 2 or more
safety and tolerability study of intravitreal vegf-trap administration in patients with neovascular amd

Conditions: Macular Degeneration

Summary: the purpose of this trial is to assess the ocular and systemic safety and tolerability of a single intravitreal injection of vegf trap in patients with subfoveal choroidal neovascularization (cnv) due to amd.

this study consists of three parts, part a, part b and part c. part a is a dose escalation. part b was terminated early. the (one) subject who received macugen is not discussed in this website. part c had subjects receive one of two doses of vegf trap (0.15 mg or 4.0 mg). this is the first study in which human subjects received intravitreal injections of vegf trap in a study eye.

Eligibility criteria:
inclusion criteria: * subfoveal cnv secondary to amd. * central retinal/lesion thickness ≥ 250µm as measured by optical coherence tomography (oct). * etdrs best-corrected visual acuity of: * 20/40 (73 letters) or worse * clear ocular media and clear lens(es) to permit good quality stereoscopic fundus photography. exclusion criteria: * prior treatment with vegf trap, bevacizumab or ranibizumab. * any investigational agent within 12 weeks of visit 2 (day 1). * presence of other causes of cnv. * active ocular infection.

Keywords: neovascular age-related macular degeneration
differences in brain derived neurotrophic factor levels between chronic and asymptomatic pain patients

Conditions: Chronic Pain

Summary: a case-control study will be conducted to analyze the differences in bdnf levels between patients with chronic pain and asymptomatic people.

brain-derived neurotrophic factor (bdnf) is considered a biomarker of brain plasticity. since different alterations in brain plasticity have been found in chronic pain patients, the investigators want to study whether there are differences at the molecular level in this population compared to an asymptomatic population in order to be able to accurately measure the impact of different physiotherapy interventions in an objective way.

Eligibility criteria:
inclusion criteria: * males and females aged 18 to 65 years with musculoskeletal pain for a minimum of 3 months * patients recruited by information pamphlets from the university clinic of the rey juan carlos university, and cseu la salle * not having received physiotherapy treatment for this same process in the last 3 months. * ability to perform all the clinical tests and to understand the study process, as well as to obtain informed consent. exclusion criteria: * systemic, neurological, oncological or inflammatory diseases; psychiatric pathologies, pregnancy, type ii diabetes.

Keywords: bdnf
digital reminiscence therapy for alzheimer's in institutionalized people

Conditions: Alzheimer Disease

Summary: digital reminiscence therapy (drt) is an innovative intervention designed to enhance the psychological health of institutionalized seniors with alzheimer's disease. this approach utilizes digital tools to facilitate the sharing of personal memories and experiences, fostering social interaction and emotional engagement. by combining technology with therapeutic reminiscence techniques, drt aims to stimulate cognitive function and improve mood, potentially alleviating symptoms of anxiety and depression commonly observed in this population. research indicates that reminiscence therapy can lead to improvements in quality of life and overall well-being for individuals with dementia. the interactive nature of digital platforms encourages participation and allows caregivers to customize content based on the individual's preferences and history. as such, drt not only serves to strengthen the connections between seniors and their pasts but also enhances their current social interactions, promoting a sense of identity and belonging. overall, drt represents a promising avenue for addressing the psychological needs of older adults with alzheimer's in institutional settings, highlighting the potential benefits of integrating technology into therapeutic practices.


Eligibility criteria:
inclusion criteria: * people over 60 years of age. * confirmed diagnosis of mild or moderate alzheimer's, where the patient still retains a certain degree of autobiographical memory. * people institutionalized in a geriatric care center or similar. * level of cognitive impairment that allows understanding and basic interaction with digital tools. * approval and signature of informed consent by the participant or his/her legal representative, demonstrating agreement to participate in the study. * availability or access to devices (tablets or computers) provided by the study program or the care center. exclusion criteria: * diagnosis of other neurological or psychiatric conditions (such as vascular dementia, parkinson's, or psychotic disorders) that may significantly interfere with the program's results. * patients in advanced stages of alzheimer's with severe limitations in remembering autobiographical events or interacting with digital devices. * vision, hearing, or fine motor problems that prevent the use of electronic devices in an appropriate manner, without the possibility of adaptation or assistance. * individuals or legal representatives who are unable or unwilling to give informed consent. * behaviors that may put the participant, staff, or other residents at risk when carrying out program activities.
etco2 level to control intraoperative bleeding and improve the quality of surgical field vision in septorhinoplasty

Conditions: Anesthesia; Carbon Dioxide; Surgical Blood Loss

Summary: it is unknown whether different end-tidal carbon dioxide pressure levels have a clinically significant effect on bleeding and surgical field quality in septorhinoplasty, especially during controlled hypotension. therefore, it was aimed to investigate the effect of ventilation strategy with controlled hypocapnia on intraoperative bleeding and surgical field quality for commonly practiced in septorhinoplasty.

septorhinoplasty is one of the most common esthetic surgeries in the world. the septorhinoplasty is accompanied by insignificant bleeding on the surgical field. excessive bleeding compromises the surgical field quality and makes more difficult the septorhinoplasty. it is very important to control and minimize excessive bleeding in surgical field by different approaches of anesthesia management. successful approaches to reduce the excessive bleeding are; controlled hypotension by keeping the mean arterial pressure in the range of 60-70 mmhg, the reverse trendelenburg position of the patient, administration of adrenaline (injection prior to surgery or packing soaked during surgery), and administration of tranexamic acid, which are applicable methods in many clinical centers. cardiac output may vary depending on the autonomic nervous system. the dominance of parasympathetic system effect may cause vasodilation, decrease in blood pressure and cardiac output. this vasodilation may increase bleeding during septorhinoplasty and worsen the surgical field quality. anesthesia management may provide a clear view for the surgeon and an improved surgical field quality. the effect of carbon dioxide on vascular reactivity deserves an extra attention in septorhinoplasty required bleeding control. the intensity of bleeding in septorhinoplasty is mainly affected by mean arterial pressure and heart rate. at the same time, blood flow can be affected directly by carbon dioxide on the smooth muscular tonus of the arterioles. after all, it is unknown whether different carbon dioxide pressure levels have a clinically significant effect on bleeding and surgical field quality in septorhinoplasty, especially during controlled hypotension. therefore, it was aimed to investigate the effect of ventilation strategy with controlled hypocapnia on intraoperative bleeding and surgical field quality for commonly practiced in septorhinoplasty.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists scores 1-3 * 18-65 years exclusion criteria: * american society of anesthesiologists scores iv, * under the age of 18, * over the age of 65, * using anticoagulant and antiplatelet drugs, * previous underwent septorhinoplasty operation, * obstetric conditions, * cardiovascular and pulmonary disease, * uncontrolled cerebrovascular disease, * allergic history to propofol, fentanyl, rocuronium, paracetamol, ibuprofen and tramadol, * refused written informed consent

Keywords: anesthesia management ent-tidal carbon dioxide bleeding quality of surgical field
nebulized hypertonic saline for inpatient use in copd

Conditions: Chronic Obstructive Pulmonary Disease

Summary: a comparison of albuterol treatments using hypertonic saline (3%) versus standard saline (0.9%) in patients with admitted patients copd in regard to modified borg dyspnea scale scores after 4 treatments within 24 hours.

hypothesis: a clinically significant difference exists between albuterol treatments with nebulized 3% saline versus standard saline, for improvements in the patient's modified borg dyspnea score during an acute exacerbation of copd.study population: this study will involve 146 patients admitted to doctors hospital in columbus, ohio from september 2014 through september 2015 with a clinical diagnosis of an acute exacerbation of copd, defined as an increase in the patient's dyspnea, cough, or change in sputum consistency/volume/color from the patient's baseline during stable conditions. study design: patients will be randomly assigned to 2.5 mg albuterol treatments with either normal saline, as is the standard, or hypertonic saline. once the patient is enrolled, they will be randomly assigned to 2.5 mg albuterol treatments with either normal saline, as is the standard, or hypertonic saline. they will then receive the 2.5mg albuterol treatment, and saline solution as determined by the randomization plan (group 1 will receive 0.9% saline and group 2 will receive 3% saline), every six hours for at least the first 24 hours, with allowance for prn (pro re nata= as needed) use every four hours by patient request. the patient's dyspnea will be evaluated prior to starting the treatment and after the intervention period is completed using the modified borg dyspnea scale.

Eligibility criteria:
inclusion criteria: * patients at least 18 years of age * admitted to doctors hospital with a clinical diagnosis of copd * documented obstruction on spirometry from prior records available at the time of the study. exclusion criteria: * patients younger than 18 years of age * spirometry data not available * history of smoking less than twenty pack-years * possibility of other primary cause of the patient's change in dyspnea or cough (e.g. pneumonia, congestive heart failure with pulmonary edema, myocardial infarction) * patient is found to have a different primary cause after initial enrollment * non-english speaking subjects
randomized study of cp-675,206 or best supportive care immediately after platinum-based therapy for non-small cell lung cancer (nsclc)

Conditions: Carcinoma, Non-small-cell Lung

Summary: the purpose of this trial is to study how long patients can remain progression free when they receive cp-675,206, compared to how long patients can remain progression free when they receive best supportive care. if you choose to take part, you will be randomized to receive either cp-675,206 as maintenance therapy or best supportive care. best supportive care means you will not receive any study drug or other treatment for your cancer. best supportive care could include treatment with antibiotics, analgesic drugs (medicine for pain), blood transfusions or psychosocial and nutritional support, depending on your needs. you have a 50% chance of being randomized to receive cp-675,206.


Eligibility criteria:
inclusion criteria: * stage iiib (with effusion) or stage iv disease that has responded or remained stable after 6 cycles of a platinum containing 1st-line regimen * patients must be able to be randomized between 3 and no more than 6 weeks after the last dose of first-line therapy. exclusion criteria: * no other systemic therapy except 1st-line platinum based treatment * symptomatic or uncontrolled brain mets or uncontrolled pleural effusions.
aflibercept compared to placebo in term of efficacy in patients treated with gemcitabine for metastatic pancreatic cancer

Conditions: Pancreatic Neoplasm

Summary: the main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (os) in participants with metastatic pancreatic cancer, treated with gemcitabine. the secondary objectives were to evaluate progression free survival, clinical benefit, overall response, safety and immunogenicity of aflibercept, in the two treatment arms (arm 1: aflibercept and gemcitabine; arm 2: placebo and gemcitabine). the study included an interim analysis of os. in accordance with the study protocol, an interim analysis was performed for the purpose of futility and overwhelming efficacy. on the basis of the interim analysis, the data monitoring committee (dmc) recommended that this study be terminated for futility based on predefined boundary rules.

the study included: * a screening visit of up to 21 days prior to randomization * randomization at baseline * a treatment period (initiated within 3 days of randomization), which included 28-day treatment cycles in both arms until predefined treatment discontinuation criteria were met * a follow-up visit 30 days after discontinuation of treatment, * a post study treatment follow-up period until death or the study cutoff date. the criteria for treatment discontinuation were: * participant (or legal representative) chose to withdraw from treatment * the investigator thought that continuation of the study would be detrimental to the participants well-being, such as: * disease progression * unacceptable aes not manageable by symptomatic therapy, dose delay, or dose modification * intercurrent illness that prevented further administration of study treatment * noncompliance with the study protocol * participant was lost to follow-up * unblinding of the participant's investigational treatment

Eligibility criteria:
inclusion criteria: * cytologically or histologically confirmed evidence of epithelial cancer (adenocarcinoma) of the exocrine pancreas * metastatic disease * no prior chemotherapy for pancreatic disease * eastern cooperative oncology group (ecog) performance status (ps) 0, 1 or 2 * adequate renal, liver and bone marrow functions exclusion criteria: * less than 42 days elapsed from prior major surgery (28 days from other prior surgery) to the time of randomization * prior treatment with anti-vegf or vegf-receptor-inhibitors * uncontrolled hypertension * pregnancy or breastfeeding * participant with reproductive potential (m/f) without effective method of contraception the above information is not intended to contain all considerations relevant to potential participation in a clinical trial.

Keywords: metastatic pancreatic cancer angiogenesis inhibitor gemcitabine
a dose range finding study to evaluate the efficacy and safety of azd9668 administered orally at three dose levels to patients with chronic obstructive pulmonary disease (copd) on treatment with tiotropium

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the primary objective is to evaluate the dose-response relationship and efficacy of azd9668 at 3 dose levels compared with placebo in symptomatic copd patients by assessing effects on lung function and symptoms of copd.


Eligibility criteria:
inclusion criteria: * diagnosis of copd with symptoms over 1 year * smokers or ex-smokers * males or post-menopausal females between 40 and 80 years old * able to use electronic devices exclusion criteria: * past history or current evidence of clinically significant heart disease * current diagnosis of asthma * patients who require long term oxygen therapy * treatment with antibiotics within 4 weeks of study visit 1b

Keywords: chronic obstructive pulmonary lung respiratory disease efficacy safety and tolerability placebo-controlled pharmacokinetics copd
a randomized, double-blind comparison of placebo and atomoxetine hydrochloride given once a day in adults with attention-deficit/hyperactivity disorder (adhd)

Conditions: Attention Deficit Hyperactivity Disorder

Summary: this is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (adhd) who are currently living in a family situation with at least one child. the primary objective of the study is to demonstrate the efficacy of atomoxetine compared to placebo in the reduction of adhd symptoms over 12 and 24 weeks of blinded treatment.

the initial study was 34 weeks long; however, the protocol was amended to extend the open-label period of the study from 8 weeks to 12 weeks (38 weeks total).

Eligibility criteria:
inclusion criteria: * meet diagnostic and statistical manual of mental disorders fourth edition - text revision (dsm-iv-tr) criteria for adult attention-deficit/hyperactivity disorder (adhd) as assessed by the conners' adult adhd diagnostic interview for dsm-iv (caadid). * have a clinical global impression for adhd severity score (cgi-adhd-s) of 4 or greater visit 2 and 3. * adult men and women age 18 years or older at time informed consent is obtained. * must be in a reciprocal relationship with a person of the opposite sex living in same defined household (cohabitating) with their spouse/significant other for a period of at least 3 months. this spouse/significant other cannot change during the study. * must have one or more children 6-17 years of age living the home as the primary residence. exclusion criteria: * anyone meeting diagnostic and statistical manual of mental disorders fourth edition (dsm-iv) criteria for any history of bipolar disorder or any history of a psychotic disorder. * anyone meeting diagnostic (dsm-iv) criteria for current major depression or current anxiety disorder. * taking psychotropic medications on a regular basis. * having any medical condition that would be exacerbated or not appropriate for inclusion in this trial. * previously taken an adequate trial of atomoxetine.